Gate Bioscience is a venture-backed, preclinical biotech company creating a new class of medicines called Molecular Gates. Our therapeutics are small molecules that aim to cure diseases by selectively eliminating harmful extracellular proteins at their origin: inside the cell. Every extracellular protein-of which there are more than 4,000-must pass through a single channel in the cell before it can be secreted into the body.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
11/01/23	$60,000,000	Series A	Andreessen Horowitz ARCH Venture Partners GV Versant Ventures	undisclosed